Miquel Bonachera, co-founder and executive director of AB-Biotics, detailed how clinical research on biotics and their health impacts has evolved, from proving probiotics’ safety to developing more targeted solutions in recent years. AB-Biotics has taken a “bottom-up” approach since its conception — identifying a strain based on its mechanism of action and then clinically demonstrating the strain’s health effect. The company has also developed products for oral and cardiovascular health.
Upcoming webinars

The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
Novonesis
Register now

From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot
Register now

Aging Is Inevitable. Longevity Is Negotiable
Sabinsa
Register now
All upcoming webinars
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement

















